



PB 40 of 2012

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 5)

National Health Act 1953

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division,
Department of Health and Ageing, delegate of the Minister for Health, make this instrument
under subsections 100(1) and (2) of the *National Health Act 1953*.

Dated 20 June 2012

FELICITY McNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing

1 Name of Instrument

- (1) This Instrument is the *National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 5)*.
- (2) This Instrument may also be cited as PB 40 of 2012.

2 Commencement

This Instrument commences on 1 July 2012.

3 Amendments to PB 79 of 2011

Schedule 1 amends the *National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011)*.

Schedule 1 Amendments

[1] Section 3, Definition for *diluent fee*

omit: \$4.75

substitute: \$4.83

[2] Section 3, Definition for *dispensing fee*

omit: \$6.42

substitute: \$6.52

[3] Section 3, Definition for *distribution fee*

omit: \$24

substitute: \$24.38

[4] Section 3 Definition for *preparation fee*

omit: \$40

substitute: \$40.64

[5] Schedule 1 Part 1, entry for Bortezomib

substitute:

Bortezomib	Powder for injection 3.5 mg	Injection	Velcade	JC	MP	C3762	D
						C3763	
						C3764	
						C3765	
						C3766	
						C3767	

[6] Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 160 mg in 16 mL with manner of administration Injection and brand DBL Docetaxel Concentrated Injection, in the column headed 'Circumstances'

insert after C3890:

C3892

[7] Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 20 mg in 2 mL with manner of administration Injection and brand DBL Docetaxel Concentrated Injection, in the column headed 'Circumstances'

insert after C3890:

C3892

[8] Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 80 mg in 8 mL with manner of administration Injection and brand DBL Docetaxel Concentrated Injection, in the column headed 'Circumstances'

insert after C3890:

C3892

[9] Schedule 1 Part 1, after entry for Irinotecan in the form I.V. injection containing irinotecan hydrochloride trihydrate 500 mg in 25 mL with manner of administration Injection and brand Irinotecan Actavis 500

insert in the columns in the order indicated:

Irinotecan Alphapharm AF MP C3184 D

[10] Schedule 2, after entry for Ondansetron in the form Tablet 4 mg (as hydrochloride dihydrate) with manner of administration Oral and brand Zofran

insert in the columns in the order indicated:

Zondan GM EMP C3050 4 0

[11] Schedule 2, after entry for Ondansetron in the form Tablet 8 mg (as hydrochloride dihydrate) with manner of administration Oral and brand Zofran

insert in the columns in the order indicated:

Zondan GM EMP C3050 4 0

[12] Schedule 2, after entry for Ondansetron in the form Tablet (orally disintegrating) 4 mg with manner of administration Oral and brand Ondansetron ODT-DRLA

insert in the columns in the order indicated:

Onsetron ODT 4 WQ EMP C3050 4 0

[13] Schedule 2, after entry for Ondansetron in the form Tablet (orally disintegrating) 8 mg with manner of administration Oral and brand Ondansetron ODT-DRLA

insert in the columns in the order indicated:

Onsetron ODT 8 WQ EMP C3050 4 0

[14] Schedule 3, after entry for GK

insert in the columns in the order indicated:

GM	Ascent Pharma Pty Ltd	68 118 734 795
----	-----------------------	----------------

[15] Schedule 3, entry for GZ

substitute:

GZ	sanofi-aventis Australia Pty Ltd	31 008 558 807
----	----------------------------------	----------------

Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the *Legislative Instruments Act 2003*. See <http://www.frli.gov.au>.